PARIS & BOSTON, April 25, 2024--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today reported its financial results for the full year 2023 and its sales for the first quarter 2024.
PARIS & BOSTON, April 24, 2024--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT) (Paris:ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced the execution of an agreement to restructure €21.3 million in outstanding debt obligations related to the Company’s finance contract with the European Investment Bank (EIB).
PARIS, April 04, 2024--Regulatory News: Mauna Kea Technologies (Paris:ALMKT):